End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.4 NZD | -0.78% | -0.62% | -3.03% |
03-08 | New Zealand Shares Jump on Friday, Fisher & Paykel Healthcare's Chair to Retire | MT |
03-08 | Fisher & Paykel Healthcare's Chair to Retire | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 27.88 times its estimated earnings per share for the ongoing year.
- The company's enterprise value to sales, at 3.64 times its current sales, is high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Electric Utilities
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.03% | 5.29B | B- | ||
+9.55% | 86.34B | B | ||
-9.64% | 16.81B | C+ | ||
+10.12% | 11.2B | C+ | ||
+43.27% | 11.15B | D+ | ||
-16.20% | 10.32B | B | ||
+6.77% | 9.08B | B- | ||
+12.09% | 6.76B | C+ | ||
+0.10% | 4.35B | - | ||
-.--% | 3.84B | - | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCY Stock
- Ratings Mercury NZ Limited